Cerenome is trading at $1.61, down 5.85%, with no clear company-specific news explaining the November 3 decline. - Cerenome’s latest reported major announcement was October 29, when it completed enrollment in its Phase 2 ReSPECT-GBM trial; that update does not establish a reason for the drop. - Broader markets were mixed: the Nasdaq was higher and the Dow lower, offering no clear explanation for Cerenome’s move. Trading volume information was not provided.